Immunotherapy and Precision Medicine: A New Era in Disease Treatment

Publication Features KIFFIK Chief Scientific Officer Gino Martini, PhD MIAMI, FL / ACCESS Newswire  / KIFFIK Biomedical Inc. ("KIFFIK"), a biotechnology company developing technology designed to provide non-invasive access to interstitial fluid (ISF) , today announced that it has been recognized as Top Biomarker Access Technology 2026 by Life Sciences Review . The recognition appears in the publication's October 2026 issue, featuring KIFFIK in an article titled "Expanding Practical, Non-Invasive Access to Interstitial Fluid." The article highlights insights from Luigi (Gino) Martini, PhD, KIFFIK's Chief Scientific Officer and CEO of PHTA Ltd, on the scientific opportunities enabled by practical access to ISF and the company's development of its proprietary K- EXP™ platform . ISF is an information-rich biological fluid that surrounds nearly every cell in the body. Although ISF has been studied for decades, practical access has historically been challenging. KIFFIK's technology is designed to provide non-invasive access to ISF, supporting new opportunities across biomarker discovery, pharmaceutical research, drug development, and longitudinal molecular measurement. "We believe access is the foundation," said Dr. Martini in the Life Sciences Review feature. "Our goal has never been just to collect another biological sample. It is to create a platform that expands practical access to meaningful biological information." The article also explores the potential for longitudinal molecular data to advance understanding of biological change over time, including applications in therapeutic response, oncology, neuroscience, and other areas of biological research. KIFFIK continues to advance its K-EXP™ platform and development programs, with a focus on expanding access to biological information and enabling new insights into human biology. Beyond his role at KIFFIK, Dr. Martini is CEO of PHTA Ltd, the University of Birmingham's flagship life sciences research and innovation facility. Learn more at PHTA.co.uk . Read the full KIFFIK Biomedical feature: Life Sciences Review - October 2026, page 33 ...Read more

Accurate and reproducible biomolecule labeling is a cornerstone of modern life science research, supporting the detailed study of cellular pathways and the creation of advanced diagnostics and therapeutics. Traditional labeling methods often depended on non-specific reactions, producing heterogeneous outcomes with inconsistent labeling and unpredictable effects on biomolecule function. Today, the field is undergoing a paradigm shift fueled by next-generation labeling chemistries—such as click chemistry, site-specific conjugation, and bioorthogonal labeling—that deliver unmatched precision and consistency. Site-Specific Conjugation: Tailoring Molecular Architectures While traditional labeling often resulted in random attachment of probes to multiple accessible sites on a biomolecule, site-specific conjugation methods represent a significant leap towards defined molecular constructs. This approach ensures that the label is attached at a predetermined, singular, or limited number of locations, resulting in highly homogeneous products with consistent properties and predictable biological behavior. The implications for reproducibility are profound, as the variability inherent in randomly labeled samples is virtually eliminated. One prominent strategy for site-specific conjugation involves the engineering of biomolecules to introduce unique reactive handles at specific amino acid residues. For instance, the incorporation of unnatural amino acids (UAAs) bearing bioorthogonal functionalities offers exquisite control over the labeling site. By genetically encoding UAAs into proteins at desired positions, researchers can create proteins with precisely positioned handles that are ripe for subsequent conjugation with a complementary probe using click chemistry or other selective reactions. This level of control is paramount for applications where the exact stoichiometry and location of the label significantly influence function, such as in the development of targeted therapeutics or molecular imaging agents. Another powerful approach leverages enzymatic modifications. Enzymes can recognize specific sequences or motifs on biomolecules and catalyze the attachment of a tag at that precise location. This "chemoenzymatic" strategy offers high specificity and efficiency, enabling the accurate functionalization of complex biomolecules, including antibodies and glycoproteins, without the need for extensive genetic manipulation. By controlling the exact site of attachment, researchers can ensure that the labeling process does not impede the biomolecule's natural interactions or function, thereby enhancing the relevance and reliability of experimental results. Bioorthogonal Labeling: Observing Biology in Its Native State The concept of bioorthogonality underpins many of the advancements in next-gen labeling chemistries. It refers to chemical reactions that can occur within a living system without interfering with endogenous biochemical processes. This allows for the labeling and tracking of biomolecules in their native cellular environment, providing insights that are unattainable with traditional, often perturbative, methods. The ability to perform chemistry "in vivo" or "in cellulo" without disrupting cellular viability or function is transformative for fundamental biological research and drug discovery. Bioorthogonal labeling strategies typically involve a two-step process: first, the metabolic or enzymatic incorporation of a small, unreactive chemical reporter (e.g., an azide or alkyne tag) into the biomolecule of interest. These reporters are designed to be inert to native biological machinery. Second, a bioorthogonal reaction, such as a copper-free click reaction, is employed to selectively attach a fluorescent probe, affinity tag, or other functional moiety to the incorporated reporter. This temporal and spatial control over the labeling event minimizes non-specific binding and off-target reactions, leading to cleaner signals and more accurate data. The impact of bioorthogonal labeling extends across various biomolecules, including proteins, nucleic acids, lipids, and glycans. For instance, the study of newly synthesized proteins or post-translational modifications can be achieved with high fidelity by incorporating modified amino acids or sugars, followed by bioorthogonal conjugation. This enables researchers to dynamically track molecular synthesis, turnover, and localization in real-time within living cells and organisms, providing unparalleled insights into cellular dynamics and disease mechanisms. The intrinsic selectivity and minimal invasiveness of bioorthogonal reactions are crucial for ensuring that the observed biological phenomena accurately reflect the system's inherent processes. Redefining Precision and Reproducibility The synergistic application of click chemistry, site-specific conjugation, and bioorthogonal labeling is fundamentally redefining precision and reproducibility in life sciences. By enabling the precise attachment of labels at defined locations on biomolecules, these chemistries generate homogeneous products with consistent properties. This homogeneity reduces experimental variability, making data more reliable and comparisons across experiments more robust. The ability to introduce labels without significantly altering the biomolecule's native function or interfering with cellular processes ensures that experimental observations accurately reflect underlying biological reality. Furthermore, the high efficiency and robust nature of these reactions contribute to superior signal-to-noise ratios in detection, leading to more sensitive and accurate measurements. The modularity of click chemistry enables the facile interchange of different reporter molecules, offering flexibility in experimental design and allowing for multiplexed analyses. This inherent versatility, combined with the unparalleled control over labeling outcomes, significantly enhances the reproducibility of results across different laboratories and experimental conditions. The evolution of labeling chemistries towards click chemistry, site-specific conjugation, and bioorthogonal approaches marks a profound advancement in the life sciences. These next-generation tools are empowering researchers with the unprecedented ability to precisely and reproducibly manipulate and observe biomolecules in their natural contexts. The resulting higher quality data and deeper mechanistic insights are poised to accelerate discovery across all facets of biological research, from fundamental cellular understanding to the development of transformative biotechnological applications. ...Read more

The biopharma GMP consulting services market in Europe is moving away from rapid expansion toward a phase of disciplined recalibration. Investment decisions are more cautious, project timelines face closer scrutiny, and compliance demands are tightening across global supply chains. Within this context, advisory partners are increasingly valued not for one time corrective actions but for delivering long term operational resilience. Engagements are being shaped by board-level concerns around continuity, inspection readiness, and reputational exposure, creating a demand profile that rewards consistency and foresight over speed. Market behavior reflects a shift toward longer relationships, narrower scopes with clearer accountability, and a preference for advisors who can move seamlessly between strategy and execution without fanfare. The sector’s value proposition is increasingly tied to stability, predictability, and the ability to absorb regulatory pressure without disrupting commercial momentum. Market Behaviour under Regulatory Compression Procurement patterns show buyers prioritising advisors who can function as extensions of internal quality leadership rather than external troubleshooters. In Europe, Budgets are being allocated with an expectation of measurable risk reduction, not generalised improvement narratives. This has led to more selective vendor rosters and a visible reluctance to onboard unfamiliar providers without demonstrated sector depth. Pricing discussions increasingly revolve around outcome alignment and retained access instead of project milestones, signalling a maturation of buying behaviour. The consulting market has responded by narrowing positioning, emphasising repeatable frameworks while avoiding claims of proprietary magic. As regulatory scrutiny intensifies unevenly across regions, demand clusters around firms able to interpret signals early and translate them into calm, defensible action. The result is a marketplace where credibility compounds slowly, relationships are guarded, and short-term wins carry less weight than dependable presence during periods of inspection or scale transition. Talent, Capacity, and Commercial Tension Labour dynamics are exerting quiet but persistent pressure on consulting capacity, shaping delivery models in subtle ways. Experienced practitioners are being deployed more strategically, while junior resources are integrated cautiously to preserve client confidence. This constraint has encouraged firms to invest in internal enablement and knowledge continuity rather than aggressive headcount expansion. Clients, for their part, are signalling fatigue with revolving teams and favour continuity even at premium rates. Contract structures reflect this shift through longer notice periods and expectations of rapid contextual fluency. Competitive differentiation increasingly stems from organisational memory and the ability to retain insight across engagements. In response, consultancies are refining governance, investing in leadership depth, and building cultures that prioritise judgment over throughput. These adaptations underscore a market that values reliability under pressure more than scale for its own sake. Opportunity Signals and Strategic Advantage Shifts in development pipelines and manufacturing footprints in Europe are opening nuanced opportunities for advisory support that blends foresight with restraint. Organisations entering new modalities or geographies are seeking counsel that can anticipate friction points without overstating disruption. This has expanded the consultative role into earlier decision windows, where influence is subtle, and success is measured by avoided missteps. Digital enablement, supplier qualification, and inspection preparedness are being approached as interconnected risk landscapes rather than isolated tasks. Firms that articulate this interconnectedness without resorting to technical exposition are gaining strategic relevance. The business value for stakeholders lies in smoother transitions, protected timelines, and leadership confidence during moments of organisational change. As margins tighten and scrutiny persists, the consulting service that prevails is the one perceived as an anchor rather than an accelerant. Across the broader biopharma landscape, the consulting services tied to GMP readiness occupy a distinctive commercial position because their impact is most visible when nothing goes wrong. This paradox shapes purchasing psychology and reinforces conservative decision-making. Stakeholders gravitate toward partners who project steadiness, discretion, and an ability to operate without spectacle. Market signals suggest continued consolidation of preferred advisors, tempered growth expectations, and heightened scrutiny of value delivery. Innovation within the sector is therefore manifesting less as new offerings and more as refined engagement models, sharper listening, and disciplined prioritisation. Firms that thrive are those aligning their internal economics with client risk horizons, accepting slower revenue recognition in exchange for embedded relevance. For buyers, the strategic benefit lies in reducing cognitive load on internal teams while maintaining confidence under regulatory observation. For providers, the opportunity rests in becoming indispensable through trust accumulation rather than visibility. Directionally, the industry appears set on a path of measured evolution, where credibility is earned incrementally and sustained performance outweighs bold claims.  In such a market, success favours patience, coherence, and an unwavering focus on outcomes that are deliberately quiet. This orientation has implications for how success is evaluated internally, shifting emphasis toward long-term assurance rather than immediate efficiency gains. Advisory relationships are increasingly framed as risk insurance embedded within operations, altering renewal dynamics and performance metrics. As regulatory expectations continue to evolve without uniform global alignment, demand favours those able to navigate ambiguity with composure. The market’s direction suggests endurance over acceleration, with durable partnerships forming the backbone of future growth. Such conditions reward organisations that balance commercial discipline with principled counsel, reinforcing the sector’s role as a stabilising force within an increasingly complex biopharma ecosystem. Momentum will accrue quietly to those prepared to invest in credibility before opportunity visibly materialises over time consistently globally. ...Read more

The pharmaceutical industry across the Asia-Pacific region, long challenged by extended development timelines and high attrition rates, is undergoing significant change with the adoption of organoid-on-chip services. These advanced microphysiological systems integrate three-dimensional cellular biology with microfluidic engineering, allowing researchers to cultivate functional, miniaturized human tissue models on transparent, chip-based platforms. As APAC strengthens its position in global biotechnology, organoid technology is becoming central to regional R&D strategies. Pharmaceutical companies are replacing traditional methods with these advanced models, which more accurately reflect human physiology. This change is both a technological and economic strategy to speed the development of life-saving therapies for a diverse and expanding population. Enhancing Predictive Accuracy through Micro-Physiological Systems The adoption of organoid-on-chip services is driven by the need for greater predictive accuracy in drug discovery and development. Traditional two-dimensional cell cultures and animal models have been essential, but they often do not replicate the complexity of human tissues, which limits their translational relevance. Organoids, which are three-dimensional constructs derived from stem cells, address these limitations by forming structures that closely resemble native human organs. They maintain cellular diversity, tissue-specific functionality, and genetic stability, allowing for more accurate disease modeling and drug response assessment. Integrating organoids with microengineered chip platforms greatly enhances their predictive capabilities. These platforms simulate key features of the human physiological microenvironment by controlling interstitial fluid flow to deliver nutrients and remove waste, mimicking blood circulation and shear stress. They also apply mechanical cues to reproduce organ-specific motions, such as lung expansion or intestinal peristalsis. Carefully regulated biochemical gradients maintain tissue-specific oxygen and nutrient levels, replicating conditions found in deep tissue or tumor microenvironments. As a result, pharmaceutical companies in the region are achieving much better clinical-to-preclinical translation. For example, liver-on-a-chip models can detect hepatotoxicity, a leading cause of late-stage drug attrition, with sensitivity above 85 percent. This performance significantly surpasses that of conventional animal models. Such accuracy allows real-time observation of cellular responses, metabolic pathways, and inter-organ interactions, ensuring that only the most promising drug candidates proceed to clinical trials. Reducing R&D Expenditure through Early-Stage De-risking The pharmaceutical industry operates under a high-stakes “fail fast, fail early” model, driven by rising costs and risks in drug development. The average cost to bring a new drug to market remains in the multi-billion-dollar range, largely due to attrition in Phase II and Phase III clinical trials. Organoid-on-chip services address this challenge by enabling earlier economic optimization in the development process, shifting potential failures from expensive late-stage trials to more efficient and informative pre-clinical stages. A key cost benefit of organoid-on-chip platforms is their reduced reliance on animal models. Animal testing, though long used for pre-clinical validation, is expensive and time-consuming. Organoid-on-chip systems use human-derived cells to provide a relevant alternative, reducing the need for large-animal facilities. By closing the interspecies “translation gap,” these models lower the risk of advancing drug candidates that succeed in animals but fail in humans, helping prevent early misdirected investment. Modern organoid-on-chip platforms now support high-throughput screening. Automated liquid handling and high-content imaging enable the parallel testing of thousands of compounds across many microphysiological chips. This scalability speeds up lead identification and optimization, producing large, high-quality datasets quickly. As a result, discovery and optimization phases that once took years can be shortened by several months, greatly improving development efficiency. Precision medicine using patient-specific models offers additional economic benefits, especially in the region. Service providers can now generate patient-derived organoids and create biobanks that capture local genetic profiles and disease subtypes. This enables pharmaceutical companies to evaluate drug efficacy in targeted demographics early in development, thereby improving clinical trial design and increasing the likelihood of success. Moving beyond a “one-size-fits-all” approach also reduces inefficiencies and allows for more strategic resource allocation. Together, these advantages lead to measurable performance improvements over traditional methods. Organoid-on-chip models offer higher predictive accuracy, better species relevance through human-centric design, and shorter lead selection timelines. Service-based models also optimize pre-clinical costs by reducing infrastructure requirements. Overall, organoid-on-chip services are essential for cost control, speed, and precision in pharmaceutical development. Integrating Automation and AI with Organoid Services The APAC region is the fastest-growing market for organ-on-chip technologies, with a projected compound annual growth rate above 29 percent through the end of the decade. A key trend in APAC is the integration of organoid-based services with artificial intelligence and laboratory automation. Leading providers are adopting digital-twin models for organ-on-chip systems. These virtual replicas improve simulation, monitoring, and optimization of biological processes, enhancing experimental efficiency and reliability. Automated cultivation is central to this workflow. Robotic platforms handle microfluidic chips, maintain stable environmental conditions, and reduce variability caused by manual handling. This automation improves reproducibility at scale and enables researchers to focus on analytical and interpretive work. AI-driven analytics enhance this ecosystem by enabling real-time interpretation of complex biological data. Deep learning algorithms analyze high-resolution organoid images to detect subtle morphological changes and biomarker expressions. These early indicators of drug response are identified sooner than with conventional observation, significantly reducing development timelines. The ongoing integration of physical experimentation and computational modeling forms a data-rich, closed-loop feedback system. Insights from organoid-on-chip experiments refine predictive models, which then inform future experimental design. This iterative process accelerates the identification of novel drug targets and enhances decision-making in early-stage development. At the same time, the region is increasingly focusing on multi-organ systems, known as “body-on-a-chip” platforms. By linking models of the gut, liver, and kidney, APAC researchers can assess how compounds are absorbed, metabolized, and excreted in an integrated system. This approach enables more accurate early evaluation of systemic toxicity and efficacy, supporting the development of therapeutics that are both more effective and safer for patients worldwide. Organoid-on-chip services have evolved from a niche academic interest to an industry standard. By focusing on predictive accuracy and economic efficiency, pharmaceutical companies in the APAC region are leading the shift toward more agile, human-relevant, and cost-effective drug discovery. ...Read more